Kirill Golovanov
AS AN Irish company now dominated by Russian shareholders, Ovoca Bio has been badly impacted by the Ukraine war and CEO Kirill Golovanov has had to develop an appropriate strategy. Investors are now waiting for the results of a delayed trial of a possible blockbuster ‘wonder drug’ but not too many are holding their breath.... Read more »
To access this content, you must be a Phoenix subscriber.
Get access to The Phoenix online for as low as €1.50 per week. Read all the regular online only Phoenix stories AND receive the packed digital edition every fortnight (25 per year). Great value for so many inside stories!
